Silke van Koningsbruggen-Rietschel, MD, PhD

Education: Study of Human Medicine

1988-1991	Ruprecht-Karls-University Heidelberg, Germany
1991	University of Rotterdam, The Netherlands (Erasmus scholarship of the EU)
1991-1993	Ruprecht-Karls-University Heidelberg, Germany
1993-1994	Internship - Scholarship DAAD (German Academic Exchange Service) Internal Medicine, Baylor College of Medicine, Houston, USA Pediatrics, University of California, San Diego, USA Surgery, Ruprecht-Karls-University Heidelberg, Germany

Residencies and Fellowships:

1995-2003	Pediatrics and Adolescent Medicine, University Children´s Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany
Since 1995	Specialized field: Pediatric Pulmonology, Allergology and Cystic Fibrosis
Since 2007	Senior Consultant in Pediatric Pulmonology, Allergology and Cystic Fibrosis University Children´s Hospital, Faculty of Medicine, University of Cologne Co-Lead of CF Centre Cologne, University of Cologne, Germany
Since 2012	Head of CF Clinical Research Centre, University of Cologne, Germany

Licensure/Board certification:

1996	Medical Doctor
2002	Pediatric and Adolescent Medicine Boards
2002	Allergology Boards
2007	Pediatric Pulmonology Boards
Since 2007	Authorisation to train in Pediatric Pulmonology and Allergology
2016	License for Genetic Consultation (German Law for Genetic Diagnostics)

Expertise:

Since 2007	Expert in European Centers of Reference Network for Cystic Fibrosis (ECORN-CF)
Since 2009	Protocol Review Committee Member of European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN)
2009	Advanced Training Course for Principal Investigators (Nov. 4-6, 2009)
2012-2015	Executive Committee Member of CTN (Clinical Trial Network) Germany
2015-2018	Co-Director of European Cystic Fibrosis Society Clinical Trial Network
2014-2020	Executive Committee Member of European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN)
2014-2016	Leadership “S3-German Guideline for Chronic Pseudomonas Infection in CF”
2015-2018	Scientific Committee Member of the European Cystic Fibrosis Society
Since 2015	Faculty Member of the European Cystic Fibrosis Society
Since 2015	Member of the European Reference Network Lung (ERN-Lung)
2017	Representative “Center for Rare Diseases - Connatal Lung Diseases” University of Cologne
2018	Habilitation at the Faculty of Medicine, University of Cologne, Germany
2018-2021	Director of the European Cystic Fibrosis Society Clinical Trial Network
2018-2021	Board Member of the European Cystic Fibrosis Society
Since 2019	Member of the Global Advisory Group on CF Clinical Drug Development
Since 2019	Member of European CF Society and Strategic Planning Task Force on Speeding up the access to new treatments
Since 2019	Reviewer for the Journal of Cystic Fibrosis and American Journal of Respiratory and Critical Care Medicine
Since 2019	Advicer for “German Center for Infection Research” for Therapeutic Development Programs in CF
Since 2021	Nomination for Trial Steering Committee HTA Project: NIHR131889 UK (A randomised open label trial to assess change in respiratory function for people with CF established on triple combination therapy (Kaftrio™) after rationalisation of nebulised mucoactive therapies (the CF-STORM trial)

Since 2020	Lead Principal Investigator for CAR-CF: Corona-Virus Disease-19 (COVID-19) Antibody Responses in Cystic Fibrosis – Pan-European Study (14 countries, 53 CF-centers)
Since 2021	Steering Committee Member for European Standards of Care
Since 2021	Steering Committee Member to organise the Scientific Program of the European Cystic Fibrosis Society Conferences

Top-10 selected Publications

The effect of TGF-beta$_1$ polymorphisms on pulmonary disease progression in patients with cystic fibrosis. T. Trojan, M. Alejandre Alcazar, G. Fink, J.C. Thomassen, M. v. Maessenhausen, E. Rietschel, P. M. Schneider and ***S. van Koningsbruggen-Rietschel*.** The effect of TGF-beta$_1$ polymorphisms on pulmonary disease progression in patients with cystic fibrosis.BMC Pulmonary Medicine 2022;22:183; doi.org/10.1186/s12890-022-01977-1.

Reduced neutrophil elastase inhibitor elafin and elevated TGFβ1 are linked to inflammatory response in sputum of CF patients with P. aeruginosa. Thomassen JC, Trojan T, Walz M, Vohlen C, Fink G, Rietschel E, Alejandre-Alcazar M.A. and ***van Koningsbruggen-Rietschel S***. ERJ Open Res 2021; doi.10.1183/23120541.00636-2020.

Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life. Selle J, Dinger K, Jentgen V, Zanetti D, Will J, Georgomanolis T, Vohlen C, Wilke R, Kojonazarov B, Klymenko O, Mohr J, ***van Koningsbruggen-Rietschel S***, Rhodes C J, Ulrich A, Hirani D, Nestler T, Odenthal M, Mahabir E, Nayakanti S, Dabral S, Wunderlich T, Priest J, Seeger W, Dötsch J , Pullamsetti S, Alejandre Alcazar M.A. Nat Commun. 2022 Jul 27;13(1):4352. doi: 10.1038/s41467-022-31655-z.

Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia. Hirani D, Alvira C M, Danopoulos S, Milla C, Donato M, Tian L, Mohr J, Dinger K, Vohlen C, Selle J , **van *Koningsbruggen-Rietschel S***, Barbarino V, Pallasch C, Rose-John S, Odenthal M, s Prhuber G, Mansouri S, Savai R, Seeger W, Khatri P, Al Alam D, Dötsch J, Alejandre Alcazar M. A. Eur Respir J. 2022 Feb 17;59(2):2002248. doi:10.1183/13993003.02248-2020. Print 2022 Feb.

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. Naehrlich L, Orenti A, Dunlevy F, …, Van Rens J, ***van Koningsbruggen-Rietschel S** and Jung A***. (*authors contributed equally) J Cyst Fibros. 2021 Apr 18;S1569-1993(21)00099-0. doi: 10.1016/j.jcf2021.03.017.

Protecting clinical trials in cystic fibrosis; COVID-19 mitigation measures crowd sourced from the European Cystic Fibrosis Society Clinical Trials Network. ***van Koningsbruggen-Rietschel S***, Dunlevy F, Bulteel V, Hayes K, Verbrugge A, Janssens H, Dufeu N, Simmonds N, Dupont L, Downey D. Trials 2021;22:578.doi.org/10.1186/s13063-021-05457-5.

SARS-CoV2 disrupts clinical research – the role of a rare disease-specific trial network. ***van Koningsbruggen-Rietschel S***, Dunlevy F, Bulteel V, Downey D, Dupont L. Eur Respir J. 2020 Aug 6:2002114. doi: 10.1183/13993003.02114-2020

Impact of COVID-19 on people with cystic fibrosis. Colombo C, Burger PR, Gartner S, ***van Koningsbruggen-Rietschel S***, Naehrlich L, Sermet-Gaudelus I, Southern K. Lancet Respir Med. 2020 May;8(5):e35-e36. doi: 10.1016/S2213-2600(20)30177-6.

Inhaled dry powder alginate oligosaccharide in cystic Fibrosis: a randomized, double-blind, placebo-controlled, crossover phase 2b study. ***Silke van Koningsbruggen-Rietschel*,** Jane C. Davis, Tacjana Pressler, Rainald Fischer, Gordon MacGregor, Scott H. Donaldson, Knut Smerud, Nils Meland, Jann Mortensen, Marie O. Fosbol, Damian G. Downey, Astrid H. Myrset, Hugo Flaten, Philip D. Rye for the SMR-2984 Clinical Trial Study Group ERJ Open Res 2020;6(4):00132-2020. doi: 10.1183/23120541.00132-2020.

GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). ***van Koningsbruggen-Rietschel S***, Conrath K, Fischer R, Sutharsan S, Kempa A, Gleiber W, Schwarz C, Hector A, van Osselaer N, Pano A, Corveleyn S, Bwirire D, Santermans E, Muller K, Bellaire S, van de Steen O. J Cyst Fibros. 2020 Mar;19(2):292-298. doi:10.1016/j.jcf.2019.09.006. Epub 2019 Oct 5